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Background: Image-based diagnosis of tumours can be advanced and improved by targeted strategies addressing
malignant molecular structures. A promising molecular target is the cholecystokinin-2-receptor (CCK2R) which can be
targeted by high-affinity peptides called minigastrins. Here we present how the imaging properties of minigastrins
tagged with near-infrared fluorescence (NIRF) dyes can be modulated by the introduction of different spacer
sequences. We identify interactions of different probe variants with regard to target affinity, specificity and
pharmacokinetic properties to optimize early detection of CCK2R-expressing tumours under clinical conditions.
Methods: Two minigastrin probes with the same near-infrared hemicyanine fluorescence dye (DY-754) for signalling
and the same CCK2R-binding peptide A-Y-G-W-M/Nle-N-F-amide but different spacers were designed as follows: ‘QE’
with three alternating D-glutamines and D-glutamic acids and ‘bivQ’ with two minigastrins, each preceded by three
D-glutamines. They were tested for affinity and specificity in vitro on CCK2R-expressing and CCK2R-non-expressing
cells. In vivo imaging was conducted with subcutaneous tumour-bearing nude mice after i.v. probe injection (54 to
108 nmol/kg) and under competitive conditions with non-fluorescent minigastrin (n = 5/group). We also assessed
probe biodistribution as well as NIRF distribution in tumour sections.
Results: Both probes showed high affinity and specificity to CCK2R-expressing cells in vitro. In vivo tumour-to-background
contrasts (tumour/background ratios (TBRs) of around 6) enabled identification of CCK2R-expressing tumours by both
probes with low accumulation in CCK2R-negative tumours (TBR of around 2). Specificity of the in vivo accumulation,
revealed by competition, was higher for QE. Besides renal retention, probe uptake into organs was very low.
Conclusion: The properties of optical minigastrin probes can be specifically modified by the introduction of spacer
sequences. A spacer of six hydrophilic amino acids increases affinity. A mix of D-glutamic and D-glutamine acids
increased target-to-background contrast. Multimerization could not increase affinity but supposedly lowered stability.
The probe QE is a promising candidate for clinical evaluation in terms of diagnosis of CCK2R-expressing tumours.* Correspondence: susanne.kossatz@med.uni-jena.de; Ingrid.Hilger@med.
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Since in neoplastic disease timely diagnosis is decisive
for survival, effective mechanisms for early tumour de-
tection are of utmost importance. One strategy to im-
prove detection is the use of targeted contrast agents,
for example nanoparticles, antibodies or peptides conju-
gated to a radioactive element or a fluorescent dye. Particu-
larly in endoscopical imaging of the colon, near-infrared
fluorescence (NIRF) molecular imaging can benefit from
the sensitivity and the real-time nature of optical imaging
without being constrained by its limited penetration depth
into tissue [1,2]. One receptor expressed in colorectal, gas-
tric and other neoplasms is the cholecystokinin-2-receptor
(CCK2R) [3-7]. This G protein-coupled receptor binds the
regulatory peptide hormones gastrin and cholecystokinin
and modified versions of them [8,9].
Peptides are an ideal basis for the development of op-
tical imaging probes. Due to their small size of less than
100 amino acids and their high permeability, they under-
lie fast bioavailability and clearance [10]. Furthermore,
they can display high receptor binding affinity and speci-
ficity without the immunogenicity of antibodies [11].
Peptide analogues of gastrin, the so-called minigas-
trins, have been shown to be very effective radiotracers
for the detection and therapy of CCK2R-expressing tu-
mours, especially medullary thyroid cancer [12-14]. In
these studies, it became obvious that the addition of a
one to seven amino acid spacer to the CCK2R binding
sequence can modify affinity, specificity, tumour uptake
and stability of the peptides [14-17].
Highest affinity and stability together with low kidney
uptake have been reported for the sequence Ala-Tyr-
Gly-Trp-Met-Asp-Phe-NH2 in combination with three
or more C-terminal D-glutamines or D-glutamic acids
[18], and additional enhancement of affinity was achieved
by dimerization of the peptide for nuclear medicine appli-
cations [19]. Now, replacement of the radioactive element
with a near-infrared dye to translate the peptide into op-
tical probes opens up a broad field of new applications not
accessible for radiotracers. Of particular interest is intra-
operative imaging and fluorescence-guided endoscopy for
high-resolution early cancer detection in colorectal cancer
screenings.
Our group recently showed that a minigastrin consisting
of a six D-glutamine spacer showed promising in vitro and
in vivo characteristics for optical imaging applications [20].
In detail, we found a low nanomolar affinity (Kd = 1.8 nM),
high binding specificity and selective fluorescence accumu-
lation in CCK2R-expressing tumours in mice.
However, for successful clinical translation, a compre-
hensive knowledge of the main pharmacological features
of minigastrin probes is fundamental. Hereto, there is an
urgent need to investigate and understand the interac-
tions of the structure of minigastrin peptides tagged withfluorescent dyes on affinity, specificity, stability and bio-
distribution. In detail, the relevance of the spacer lengths
and the amino acid hydrophilicity and charge on probe
targeting and optical imaging properties should be eluci-
dated. Another important point is whether multivalency
can improve affinity also in optical minigastrins as it has
already been shown for nuclear medicine applications.
To investigate these relationships, we designed two
new optical minigastrin probes with different spacer se-
quences. Firstly, to assess the influence of amino acid
charge and hydrophilicity, we introduced a spacer of
three neutral D-glutamines and three negatively charged
D-glutamic acids; this strategy reduces the negative
charges compared to the recently published probe [20].
Secondly, we investigated the targeting and imaging
properties of a dimerized minigastrin, where a spacer of
three neutral D-glutamines preceded each minigastrin
molecule to gain further insight into the influence of
multimerization and spacer lengths on affinity, specifi-
city and stability.
Methods
Design of the optical probes
Two variants of NIRF cholecystokinin-2-receptor target-
ing peptide probes were fabricated. Both were based on
the CCK2R binding peptide sequence Ala-Tyr-Gly-Trp-
Met/Nle-Asp-Phe-amide that shows high affinity to the
CCK2R [21,22], but differed in the N-terminal amino
acids (‘spacer sequence’) to investigate the influence of
different spacer variants on affinity, specificity and pharma-
cokinetic properties of the peptides. The spacer of probe
QE consisted of three alternating neutral D-glutamines
and negatively charged D-glutamic acids each [13,17,23]
(Figure 1a). The probe bivQ had a bivalent character, in
which two minigastrin sequences, each of them consisting
of a spacer of three D-glutamines, were connected to the
fluorochrome (Figure 1b). We calculated ALogP values of
the compounds using the fragmental method employed in
the SymyxDraw software [24]. Peptides were synthesized,
purified and lyophilised (Peptide Specialty Laboratories,
Heidelberg, Germany), followed by conjugation to the
N-Hydroxysuccinimid of the NIR fluorochrome DY-754
(Dyomics GmbH, Jena, Germany; absorption 748 nm,
emission 772 nm). We selected the fluorochrome DY-754
due to its low non-specific binding to tissue and renal elim-
ination properties as it has been described previously [20].
Cell culture
A431/CCK2R and A431/WT, human epidermoid carcin-
oma cells, were a gift from Dr. Luigi Aloj (Department
of Nuclear Medicine, Instituto Nazionale Tumouri,
Fondazione ‘G. Pascale’, Naples, Italy). The cells were stably
transfected with either the CCK2 receptor (A431/CCK2R)







Figure 1 Structural formulas of optical CCKR binding peptide probes. (a) The probes differed in the spacer sequence connecting the NIR
fluorochrome DY-754 and the CCK2R binding peptide. The probe QE displayed a spacer of three negatively charged D-glutamic acids alternating
with three D-glutamines. (b) The probe bivQ had a bivalent nature, where each of the two minigastrin sequences was preceded by a spacer of
three D-glutamines. Structural formulas were drawn with SymyxDraw.
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für Mikroorganismen und Zellkulturen) in 2012. Cells were
grown in a monolayer culture at 37°C in a 5% CO2 hu-
midified atmosphere and were maintained in D-MEM
medium with 10% (v/v) FBS (Invitrogen) and passaged
regularly at 70% to 80% confluency.
Animals
Female athymic nude mice (Hsd:Athymic Nude-Foxn1nu
nu/nu; Harlan Laboratories, Eystrup, Germany) were
housed under standard conditions with water and
food ad libitum. Mice were maintained under a low-
pheophorbide diet (C 1039; Altromin, Lage, Germany) to
reduce tissue autofluorescence. All procedures were ap-
proved by the regional animal committee (reg. number
02-007/10) and were in accordance with international
guidelines on the ethical use of animals. Animals were
anesthetized with 2% isoflurane during all procedures. To
implement subcutaneous xenografts, 5 × 105 CCK2R trans-
fected (A431/CCK2R) and non-transfected wild-type cells
(A431/WT) were dispensed in Matrigel™ (BD Biosciences,
Heidelberg, Germany) and injected into the right (A431/
CCK2R cells) and left (A431/WT cells) flank of 8- to
12-week-old animals 10 to 15 days before in vivo imaging.Target binding in vitro
Binding of the optical probes QE and bivQ to CCK2R-
expressing (A431/CCK2R) and CCK2R-non-expressing
(A431/WT) cells was investigated after incubation with
0.5 μM of each probe in culture medium for 30 min at
4°C to observe active surface receptor binding and at
37°C to check for internalization behaviour, which is
mandatory for in vivo signal amplification. Incubation
with 0.5 μM of the fluorochrome DY-754 should deter-
mine the role of the interaction of the peptide with the
CCK2R for probe uptake. Probe incubation was followed by
cell membrane staining with wheat germ agglutinin-Alexa
Fluor®-555 (WGA-555, Invitrogen, Carlsbad, CA, USA),
fixation in 4% (v/v) paraformaldehyde on ice and mount-
ing in PermaFluor® Mounting medium (Thermo Fisher,
Waltham, MA, USA), containing 0.2 μg/mL Hoechst
33258 (Applichem, Darmstadt, Germany) to stain cell
nuclei. Fluorescence microscopy was carried out with
the digital microscope EVOSfl (AMG, Bothell, WA,
USA) equipped with three filter cubes for visualization of
Hoechst (excitation 335 to 379 nm, emission 417 to
477 nm), WGA-555 (excitation 511 to 551 nm, emission
573 to 613 nm) and DY-754 (excitation 690 to 730 nm,
emission 752 to 798 nm).
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To semiquantitatively assess affinity of the optical probes
to the CCK2R, we employed an empirical method, which
is based on the determination of the fluorescence inten-
sity of cells after probe incubation according to [26].
The dissociation constant Kd was calculated from a sat-
uration binding curve where we incubated 2 × 106 A431/
CCK2R cells with 0.1 to 50 μM of probe for 5 min at
room temperature. Fluorescence intensities of cell pellets
were measured using a NIRF small-animal scanner
(Maestro®, CRi Inc., Woburn, MA, USA) following a
procedure described previously by our group [20].
Binding specificity
Determination of the binding specificity was carried out
by preincubating cells with increasing concentrations of
unlabelled peptide (HG-13 Minigastrin, Bachem, Weil
am Rhein, Germany) ranging from 0.1 to 2,000 nM dir-
ectly before adding a fixed probe concentration of 2 nM
to all samples. Thereafter, fluorescence intensities of cell
pellets were measured using a NIRF small-animal scan-
ner (Maestro®, CRi) and analysed semiquantitatively ac-
cording to [20].
In vivo imaging of xenograft-bearing nude mice
Xenografts were inoculated in athymic nude mice (Hsd:
Athymic Nude-Foxn1nu nu/nu; Harlan Laboratories) 10
to 15 days before imaging by subcutaneous injection of
0.5 million A431/CCK2R (left flank) and A431/WT cells
(right flank) dispersed in Matrigel™ (BD Biosciences).
For in vivo fluorescence imaging, 108 nmol/kg QE or
54 nmol/kg bivQ probe was injected intravenously (i.v.),
according to the results of a dose determination experi-
ment, which was set up to identify the optimal relation
between sensitivity and contrast (Additional file 1).
Apart from the study group, one group of animals re-
ceived the respective optical probe together with a
10-fold excess of unlabelled minigastrin to induce a
competition for CCK2R binding and therefore revealing
in vivo specificity. Another group received 108 nmol/kg of
the unconjugated fluorophore DY-754 to determine dye-
mediated non-specific tumour uptake, and one group
remained untreated to control for probe-unrelated NIR
fluorescence in the animals. At defined time points be-
tween 0 and 8 h p.i., NIRF fluorescence images (excitation
615 to 665 nm, emission >750 nm) and white light images
of the animals were obtained. By means of spectral unmix-
ing, tissue autofluorescence was removed from the images.
Subsequently, fluorescence intensities (FI) were analysed
over the time in regions of interest (ROIs) that were
placed upon the tumours and non-tumour tissue. As a
measure of contrast between tumour and non-tumour
fluorescence, tumour/background ratios (TBRs) were cal-
culated as a quotient of FItumour/FInon-tumour.Biodistribution
We investigated the biodistribution of the optical probes
and of the fluorochrome DY-754 to determine the influ-
ence of the dye on tumour and organ accumulation.
Therefore, 8 h p.i., ex vivo NIRF fluorescence images of
the organs and the two xenografts (A431/CCK2R and
A431/WT) per mouse were taken in combination with
the placement of ROIs on these organs to assess semi-
quantitative fluorescence intensities.
Ex vivo probe distribution measurement
To determine intratumoural distribution of the peptide
probes ex vivo, acetone-fixed 30-μm cryosections of
explanted xenografts were scanned mesoscopically in
the near-infrared scanner Odyssey® (LI-COR, Bad Homburg,
Germany) at 700 nm (autofluorescence) and 800 nm (probe
fluorescence).
Immunohistochemistry
To verify the CCK2R expression in xenografts, 3-μm
paraffin-embedded sections from explanted tumours were
deparaffinised and antigens were demasked by microwave
treatment (25 min, 200 W). Then, sections were blocked
with goat serum and avidin/biotin block (Dako) before
primary anti-CCK2R antibody incubation (15 ng/mL
(PAB6796, Abnova, Heidelberg, Germany) in 3% BSA
(w/v)) for 1 h, followed by secondary antibody incuba-
tion (0.36 μg/mL (Dianova, Hamburg, Germany) in 3%
BSA (w/v)) for 1 h. Afterwards, alkaline phosphatase
(AP)-conjugated streptavidin (Biozol, Eching, Germany) was
used with chromogens from an AP detection system
(K5005, Dako, Glostrup, Denmark) for detection. Cell nuclei
were counterstained with Mayer's hematoxylin (Fluka/
Sigma-Aldrich, Steinheim, Germany) and mounted with gel-
atine (SERVA Electrophoresis, Heidelberg, Germany).
Statistics
Statistical significance between experimental groups was
calculated using two-sample t test for independent
samples. Significance levels were chosen as p < 0.05
and p < 0.01. All experiments were repeated at least
three times, and all in vivo animal groups consisted of
at least five animals.
Results
Probe binding to target and internalization in vitro
The probes QE and bivQ showed comparable binding and
internalization at the physiologically relevant temperature of
37°C only to CCK2R-transfected A431 cells (Figure 2a,b).
The involvement of active receptor binding in uptake was
revealed by probe incubation at 4°C, where probe binding
was confined to the cell membrane (Figure 2c). A431/WT
(no CCK2R expression) cells displayed no binding of the
QE and bivQ, as exemplarily shown for bivQ, confirming
a b c
d e f
Figure 2 The optical probes QE and bivQ showed specific binding and internalization in A431/CCK2R cells. We found intracellular uptake
into A431/CCK2R cells at 37°C for the probes (a) QE and (b) bivQ and (c) cell membrane binding at 4°C (exemplarily for bivQ). (d) A431/WT cells
showed no probe uptake at 37°C (exemplarily for QE). (e) Native A431/CCK2R showed no fluorescence in the NIR spectrum. (f) Similar
internalization into A431/CCK2R cells was observed for the probe dQ-MG-754 [20] at 37°C. Displayed are representative fluorescence microscopy
images of n = 3 experiments. Colour coding: red, DY-754 spectrum; green, cell membrane stain WGA-555; blue, cell nuclei stained with Hoechst
33258. Bars measure 100 μm.
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sence of NIR fluorescence in native A431/CCK2R showed
that no probe-unrelated fluorescence/autofluorescence oc-
curred (Figure 2e). Specificity of the detected fluorescence
and probe-target interaction was further supported by the
fact that no NIRF signal was detected in native A431/WT
cells and in A431/CCK2R and A431/WT cells after incu-
bation with the fluorochrome DY-754 (Additional file 2).
Compared to the CCK2R-targeted peptide probe dQ-MG-
754 [20], we detected no differences in binding and in-
ternalization properties of the probes QE and bivQ at
37°C (Figure 2f ).
Binding affinity to CCK2R-expressing cells
The optical probes QE and bivQ showed a dissociation
constant below the already-established high affinity thresh-
old of 10 nM [27]. We detected identical Kd values of
5.8 ± 0.6 nM (QE) and 5.8 ± 1.6 nM (bivQ), despite the
different D-glutamic acid and D-glutamine spacers and
bivalency of bivQ (Figure 3a).
Binding specificity
A high specificity of the probe-receptor interactions
could be demonstrated by blocking CCK2R binding posi-
tions with increasing concentrations of non-fluorescent,
competitive minigastrin before addition of a fixed concen-
tration of one of the optical probes. Probe binding de-
creased with increasing concentrations of non-fluorescent
minigastrin, demonstrating that the non-fluorescent mini-
gastrin and the optical probes competed for the same, fi-
nite number of binding sites (Figure 3b). A relatively
low competitor concentration of 16.7 ± 0.2 nM (QE)and 16.6 ± 0.2 nM (bivQ) led to a reduction of the ini-
tial binding by 50%, indicating that the specificity of
the probes QE and bivQ was high and that no distinct
influence of the different spacer compositions was de-
tected (Figure 3b).
In vivo imaging features of xenograft-bearing nude mice
Before starting the in vivo experiments, we assessed the
metabolic stability of the probes against degradation by
proteases (Additional file 3) and found that QE was
more stable than bivQ, but both probes showed a stabil-
ity against proteolytic degradation to be promising can-
didates for in vivo imaging.
Both optical probes, QE and bivQ, allowed to clearly
detect subcutaneously implanted CCK2R-expressing tu-
mours in vivo in nude mice, due to up to six times
higher fluorescence intensity in A431/CCK2R tumours
compared to non-tumour tissue (equals tumour to back-
ground ratio, TBR). A431/WT tumours, on the other
hand, displayed negligible contrast between tumour and
non-tumour tissue due to a lack of probe accumulation
(Figure 4a). High contrasts in A431/CCK2R tumours be-
came visible already 2 h after i.v. injection, which were
comparable for both probes. The highest contrast images
were captured between 2 and 8 h p.i. Although the spe-
cific tumour fluorescence signals became weaker over
the time, it was easily possible to detect tumours up to
72 h after i.v. probe injection (Figure 4b). As a conse-
quence of specific binding, fluorescence was retained in
A431/CCK2R tumours, but not in A431/WT tumours
and normal tissue, leading to the observed contrasts be-
tween CCK2R-expressing tumours and the background
ab
Figure 3 The probes QE and bivQ showed high affinity and specificity to A431/CCK2R cells. (a) Determination of affinity revealed
dissociation constants of 5.8 ± 0.9 nM for QE (left) and 5.8 ± 1.6 nM for bivQ (right). (b) Specificity of CCK2R binding was evaluated after
blocking with increasing amounts of non-fluorescent CCK2R ligand. A competitor concentration of 16.7 ± 0.2 nM (QE, left) and 16.6 ± 0.2 nM
(bivQ, right) led to a reduction of the initial binding by 50%. Displayed are means and standard errors of three individual experiments with
two parallels each.
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754 fluorochrome, we also observed strong fluorescence
in the whole animal. However, the fluorescence from tu-
mours and surrounding tissue decreased in the same
manner, meaning that dye-mediated tumour uptake and
retention of the optical probes were negligible.
Specificity of probe accumulation could be verified be-
cause in vivo competition of the probes with non-fluorescent
minigastrin, which was injected simultaneously with the
probe in a 10-fold molar excess, led to reduced fluorescence
intensities in A431/CCK2R tumours (Figure 5a). The probe
QE showed a high initial TBR of 6.2 ± 1.0 8 h p.i. in A431/
CCK2R xenografts, and competition with non-fluorescent
minigastrin reduced the TBR significantly to 4.4 ± 0.9
(p = 0.02). This reduction due to competition was sig-
nificant (p < 0.05) between 1 and 8 h p.i. in A431/
CCK2R tumours. A431/WT tumours displayed TBRs
around the value of 2 that were not influenced by com-
petition (Figure 5b (I)). The bivalent probe bivQ
achieved TBRs comparable to QE, reaching a value of
6.3 ± 1.4 8 h p.i. that was reduced to 4.0 ± 1.2 after
competition (p = 0.02). In this case, a significant TBRreduction could not be observed for all time points be-
tween 1 and 8 h p.i., and significance levels were lower
than for QE (Figure 5b (II)). Interestingly, TBRs of
A431/WT tumours also showed a significant change
under competitive conditions after 1 to 4, and 8 h p.i.,
although the TBR values stayed at a low level between
1 and 2.
Hence, high TBRs were observed for QE and bivQ, but
for QE with negatively charged D-glutamic acids, probe
accumulation could be reduced more distinctly by indu-
cing competition for specific CCK2R binding sites,
showing higher specificity in vivo compared to bivQ.
Biodistribution
Analysis of fluorescence distribution in the organs
and the two xenografts in each mouse revealed strong
fluorescence accumulation only in A431/CCK2R tu-
mours and the kidneys of the animals (Figure 6a,b).
In particular, the negatively charged probe QE showed
a kidney accumulation that was four times higher
than that of the more neutral probe bivQ, taking into
account, however, that QE was injected in double
Figure 4 In vivo imaging of A431/CCK2R tumours and probe kinetics of QE and bivQ. (a) The probes QE and bivQ clearly depict A431/CCK2R
but not A431/WT subcutaneous xenografts in vivo. (b) Tumours could be detected up to 72 h after probe injection. (c) Semiquantitative fluorescence
signal intensities from 0 to 8 h p.i. for QE, bivQ and DY-754 in A431/CCK2R tumours, A431/WT tumours and normal tissue. Means and standard
deviations of n = 5 animals. All images were obtained with a NIRF small-animal scanner (excitation 615 to 665 nm, emission >750 nm), thresholded
for their fluorescence intensity (blue, lowest FI; red, highest FI) and overlaid with their respective white light image. Plus sign, A431/CCK2R tumour;
minus sign, A431/WT tumour.
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bivQ into A431/WT tumours was also confirmed,
which was comparably high for the fluorochrome DY-
754 (p > 0.05). We observed a weakly elevated uptake
of QE in the liver compared to the free DY-754. The
brain, lung, heart, spleen and muscle displayed fluor-
escence intensities that were comparable to the re-
spective tissue samples, which were exposed to the
free DY-754 (Figure 6c) and slightly elevated com-
pared to native animals (Figure 6d).
The stomach, small intestine and colon showed no
fluorescence accumulation of the probes QE, bivQ or
the fluorochrome DY-754, supporting the observation
that the molecules are excreted renally and not through
the hepatobiliary system (Figure 6).Ex vivo probe distribution in tumours
The probe distribution pattern within tumours was inde-
pendent from the structural properties of the probes.
We detected strong fluorescence signals at 800 nm
(emission maximum of the NIRF probes) for QE and
bivQ only in the outer A431/CCK2R tumour regions
and not in the central parts, where necrosis occurred
(Figure 7a). In vivo application of the DY-754 fluoro-
chrome did not result in fluorescence at 800 nm neither
in A431/CCK2R nor in A431/WT tumours. Any inter-
ference with autofluorescence could be excluded since
fluorescence of all tumours at 700 nm was uniform and
distinctly lower than at 800 nm (Figure 7a).
The intratumoural probe distribution was also consist-
ent with immunohistochemistry of CCK2R expression.
Figure 5 Tumour accumulation of the probes QE and bivQ in vivo was highly specific. (a) Reduction of the fluorescence signals under
competitive conditions for QE (I) and bivQ (II). (b) TBRs significantly decreased in A431/CCK2R tumours, but not in A431/WT tumours under
competitive conditions for QE (I) and bivQ (II). *p < 0.05, **p < 0.01 (Student's t test). Means and standard deviations of n = 5 animals were
calculated. Images were obtained with a NIRF small-animal scanner (excitation 615 to 665 nm, emission >750 nm), thresholded for their maximum




Figure 6 Biodistribution of QE, bivQ and DY-754 8 h p.i. in mice carrying A431/CCK2R and A431/WT xenografts. Semiquantitative
fluorescence signals of tumours and organs injected with (a) QE, (b) bivQ and (c) DY-754, or (d) native animals. Bars represent means and standard
deviations for n = 5 animals. *p < 0.05, **p < 0.01 (Student's t test of QE or bivQ versus DY-754).





Figure 7 QE and bivQ probe showing specific accumulation in vital regions of A431/CCK2R, but not of A431/WT tumours. (a) Ex vivo
fluorescence images of tumour slices of animals that were injected with QE, bivQ and DY-754. The last column shows the native tumours. Images
were obtained with an Odyssey slide scanner at 700 nm (autofluorescence) and 800 nm (probe fluorescence). All images are comparable in
terms of their fluorescence intensity (white, lowest FI; black, highest FI). Representative images of three specimens/group are displayed.
(b) Immunohistochemical staining of CCK2R in A431/CCK2R and A431/WT tumours. Red, CCK2R staining (see ‘Methods’); blue, cell nuclei
staining with Mayer's haematoxylin.
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CCK2R tumours, whereas the staining was negative in
A431/WT tumours (Figure 7b).
Discussion
Our investigations revealed that the distinct spacer com-
positions of the probes QE and bivQ influenced all
in vivo specificity, stability and kidney uptake above.
Compared to other optical minigastrin probes, in vivo
tumour-to-background contrast was markedly increased.
The negatively charged D-glutamic acids of the probe
QE led to the highest TBRs and best in vivo specificity
and stability against proteases. The bivalent nature of
the bivQ probe, however, was not adequate to increase
target affinity, as observed for other multimeric small
molecules.
In vitro probe characteristics
We could confirm that binding characteristics of optical
minigastrin probes are influenced by the spacer se-
quence, which connects the imaging moiety with the
binding moiety, as it was published for radiolabelled
minigastrin probes e.g. [14,28-30]. The in vitro experi-
ments demonstrated that the structure of CCK2R-
targeted NIRF probes QE and bivQ mainly influenced
metabolic stability, whereas in vitro specificity was not
altered. Both probes showed a high affinity binding
(QE, Kd = 5.8 ± 0.6 nM; bivQ, Kd = 5.8 ± 1.6 nM). How-
ever, the minigastrin peptide with a spacer of six uncharged
D-glutamines (dQ-MG-754, [20]) revealed even a
higher binding affinity (Kd = 1.8 ± 0.6 nM, [20]). Thisis an indication that this spacer is slightly advanta-
geous in terms of affinity compared to a spacer with a
combination of three D-glutamines and three D-glutamic
acids (QE) or a spacer with three D-glutamines and a bi-
valent peptide construct (bivQ).
Surprisingly, no increased affinity was detected for the
bivalent probe bivQ, albeit multimeric variants of small
molecule probes have been reported to be of superior
target affinity before [31]. For example, an affinity in-
crease was reported for RGD peptides for nuclear medi-
cine applications, which was proportional to the number
of oligomerically combined RGD units [32,33]. Also, a
radiolabelled bivalent minigastrin, different from the one
in this paper, showed a sixfold higher tumour uptake
compared to its monovalent variant [19]. A possible in-
fluence of the dye moiety on affinity is discussed below.
Possibly, an increase in affinity by multimerization of
CCK2R-targeted peptides can only be achieved by fol-
lowing defined basal design principles which consider
that a multivalent probe has more than one possibility
to bind to the target structure. It might be advantageous
to choose a low-affinity minigastrin for multimerization
because this increases the possibility that more than one
binding event per molecule can occur before internaliza-
tion prevents further multivalent interactions. Alterna-
tively, the use of non-internalizing minigastrin antagonists
might also provide a high potential to increase affinity for
multivalent high-affinity probe constructs [34].
Regarding the influence of the dye conjugation on
probe affinity, previously published results on analogous
minigastrin variants as radioligands revealed dissociation
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et al. 2011 [13] reported a Kd value of 9.0 ± 4.2 nM for
the radiotracer analogue of QE and 4.8 ± 4.2 nM for the
monovalent radiotracer version of bivQ. Hence, no loss
of affinity occurred through the conjugation of the fluoro-
chrome DY-754, opposed to former optical probes, where
affinity decreased after dye conjugation compared to un-
conjugated or radioactively labelled peptides [11,35,36].
This is ascribed to the particular features of the
fluorochrome DY-754, such as high hydrophilicity, low
non-specific binding to tissue and renal elimination
properties [20]. Therefore, the dye conjugation comple-
mented probe characteristics by sterical stabilization of
the molecule construct.
As we could show, the optical probes QE and bivQ
bound specifically to CCK2R-expressing cells. Moreover,
they were actively internalized at a temperature of 37°C
but restricted to the cell membrane at 4°C. Thus, intern-
alization behaviour was not qualitatively influenced by
the different spacers and was not impeded by the dye
conjugation. Successful internalization of ligand-receptor
complexes has been described as a hallmark for success-
ful tumour targeting, since retention time is prolonged
and cumulative accumulation leads to signal multiplica-
tion in tumour tissue [37], while non-internalized probe
molecules are cleared from blood and tissues [38,39].
These effects ultimately lead to an augmented sensitivity.
The probe QE was evaluated to be highly stable against
degradation by liver proteases. After systemic application
into the blood system where the protease density is lower
than in liver tissue [17], the probe is likely to show up a
comparatively higher stability. The probe bivQ, however,
elicited only a limited metabolic stability in the presence
of liver proteases. This is an indication that the metabolic
stability of the probes was sufficient to reach the target
site in its original constitution in our in vivo experiments,
where we demonstrated specific targeting of CCK2R-
expressing tumours. Compared to a previously published
optical minigastrin probe [20] (Additional file 4), the nega-
tively charged D-glutamic acids of the probe QE strongly
improved enzymatic stability, whereas the bivalent consti-
tution seems to increase the vulnerability of the molecule
to proteases. Furthermore, the long spacer of six hydro-
philic amino acids in QE seemed to be superior over the
shorter three amino acid spacer in bivQ.
The high affinity binding of the probes QE and bivQ
to the CCK2R in combination with internalization and
hence signal amplification is an important prerequisite
for low dosage for the prospective detection of CCK2R-
expressing tumours in the clinical application due to a
high contrast between malignant and healthy tissue. Par-
ticularly for small molecule probes, a dissociation con-
stant of 0.1 to 10 M is needed for maximal tumour
accumulation. Small molecule probes quickly achievehigh tumour concentration levels but require high affin-
ity to be retained, as unbound molecules are cleared rap-
idly from the tumour [40]. Due to its comparatively high
metabolic stability, the probe QE elicits better perspec-
tives for CCK2R imaging probes over the probe bivQ.
In vivo imaging capabilities
In vivo small-animal imaging revealed that the new op-
tical probes QE and bivQ were capable of high-contrast
imaging of CCK2R-expressing xenografts (TBR > 6). They
showed a strong specificity of tumour accumulation. The
corresponding TBRs were around one-third higher TBRs
than that of the previously published probe dQ-MG-754
(TBR > 4, [20]) but a comparably weak non-specific accu-
mulation in A431/WT tumours (TBR < 2). Hence, both
spacer modifications, the introduction of negatively
charged D-glutamic acids in QE and the bivalency of
bivQ, increased TBRs.
In terms of specificity, competitive conditions for
CCK2R binding diminished the TBRs significantly in
both cases, for QE and bivQ, by 30% to 40%, a high
value for an only 10-fold excess of unlabelled peptide.
Compared to dQ-MG-754 [20], where TBRs were re-
duced by 50%, competition was less complete for QE
and bivQ, indicating elevated unspecific binding in vivo;
the reasons of which remain to be identified. However,
this might partly be due to the lower initial TBR of dQ-
MG-754 of around 4 (compared to > 6 for QE and
bivQ).
Importantly, we observed an absence of fluorescence
signals in the gastrointestinal tract for QE and bivQ,
resulting from the hydrophilicity-induced renal elimin-
ation pattern. The strongly negative ALogP values fur-
ther support the high hydrophilicity of the molecules. A
former optical minigastrin probe with a spacer of hydro-
philic glutamic acids, but the less hydrophilic fluorescent
dye DY-676, displayed predominantly a hepatobiliary
elimination [41], underlining once more that probe char-
acteristics are always a summation of peptide and dye
properties and that selection of the dye can fundamen-
tally change probe characteristics. With consideration of
fluorescence-guided endoscopy, hepatobiliary elimin-
ation could lead to strong non-specific fluorescence sig-
nals in areas contaminated by faeces remaining after
incomplete colonic irrigation, which would obscure spe-
cific fluorescence signals [36].
The renal elimination pattern that was successfully
achieved by the probe design was accompanied by
prominent renal retention. This was unexpected, since
the radioligand variants of the probe QE as well the dye
DY-754 showed a renal elimination as well but only a
minimal kidney retention [20,23]. Therefore, we assume
that the combination of the four negatively charged sulfo
groups of the fluorochrome DY-754 together with the
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tention. Several studies have shown that an alteration of
positively or negatively charged amino acids can influ-
ence the renal uptake pattern of peptides [23,30,42].
Possibly, after glomerular filtration followed by receptor-
mediated endocytosis (e.g. megalin receptor) in the prox-
imal tubules, the probe constructs exhibit different
accessibility to lysosomal degradation and hence dif-
ferent retention times [43]. The observation that the
renal fluorescence of the probe QE was twice as high
as that from the probes bivQ and dQ-MG-754 [20]
implies that additional D-glutamic acids are degraded
slower than D-glutamines. As long as areas other
than the kidney are investigated, kidney retention will
not negatively influence the imaging process. The biocom-
patibility of the optical minigastrin dQ-MG-754 has been
already proven, where kidney cell growth in vitro was not
diminished by the exposure to high concentrations of the
probe. Accordingly, therefore, nephrotoxicity is unlikely to
occur in vivo [20].
Our investigations have unveiled the influences of the
probe constitution on imaging properties. In detail, the
D-glutamines influenced especially affinity, specificity
and biodistribution in a positive way. Additional D-glutamic
acids can be applied to increase tumour-to-background con-
trast and metabolic stability, as shown here for the probe
QE. Bivalency of two high-affinity minigastrins did not lead
to an enhanced affinity but decreased stability. Whether
these results are of general significance for peptide probes or
are confined to optical minigastrins only should be eluci-
dated in the future using other optical peptide constructs,
for example for bombesin or somatostatin probes. Today, a
large variety of near-infrared dyes are available, which can
also be customized to possess a defined number of negative
or positive charges. Hence, by selection of a defined dye and
spacer, affinity and pharmacokinetic properties of small mol-
ecule probes can be selectively influenced.
Conclusion
Our investigations revealed that the new optical probes
QE and bivQ were feasible for high-contrast imaging of
CCK2R-expressing xenografts in mice and showed a
strong specificity of tumour accumulation. For further
testing in humans, we favour the probe QE; because of
the applied probe design strategies, the introduction of
negatively charged D-glutamic acids favoured probe
characteristics more than multimerization of the mol-
ecule. Combining two high-affinity minigastrins into a
bivalent construct turned out not to further enhance
affinity but to increase proteolytic degradation. Hence,
multimerization of minigastrins seems to be less effect-
ive than variation of a hydrophilic six-amino acid spa-
cer in a monovalent molecule, as shown for the probe
QE. Our results help to better understand the consequencesof spacer design in optical small molecule probes with the
aim to build an optimal probe construct. A CCK2R-targeted
optical probe with low nanomolar affinity and high specifi-
city, renal elimination and increased metabolic stability will
have the best prerequisites for reliable clinical endoscopical
examinations.
Additional files
Additional file 1: Dose determination of NIRF probes for in vivo
experiments. (a) Average fluorescence signals with time and (b) TBRs of
CCK2R expressing tumours were determined for 4 to 216 μmol/kg i.v.
injected probe. Higher probe concentrations led to higher fluorescence
signals but lower specific contrasts. Lower probe concentrations led to
higher contrast but were limited by sensitivity. Accordingly, the probe
concentrations for in vivo experiments were chosen. Data represent one
animal per concentration. All data were obtained with a NIRF small-animal
scanner (excitation 615 to 665 nm, emission > 750 nm).
Additional file 2: Confirmation of specificity for CCK2R targeted
probe binding by negative controls. (a) Native A431/WT cells
displayed no NIRF signal. After incubation with DY-754, neither (b) A431/
CCK2R nor (c) A431/WT cells showed NIRF fluorescence. Displayed are
representative fluorescence microscopy images of n = 3 experiments.
Colour coding: red, DY-754 spectrum; green, cell membrane stain WGA-555;
blue, cell nuclei stained with Hoechst 33258.
Additional file 3: Metabolic (protease) stability of QE and bivQ
against the degradation by mouse liver homogenates. The HPLC
peak of non-degraded QE at 9.7 min elution time (a-I) decreased after
180 min of probe incubation in liver homogenate, whereas a second
peak, representing degradation products, appeared at 7.2 min of elution
(a-II). Degradation curves of (b) QE and (c) bivQ. The grey line in (a) displays
the acetonitrile gradient (percentage in A.bidest/0.1% trifluoroacetic acid).
Peaks were detected at 750 nm with a UV/VIS detector. Data represent three
parallels.
Additional file 4: Metabolic stability of the optical CCK2R targeted
minigastrin dQ-MG-754 [20]. Degradation of dQ-MG-754 for comparison
with QE and bivQ. Metabolic stability against degradation by mouse liver
proteases is higher than for bivQ but lower than for QE. Probe signal was
detected at 750 nm with a UV/VIS detector. Data represent three parallels.
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